Oric Pharmaceuticals insider sells 13,100 shares

Rhea-AI Filing Summary

Oric Pharmaceuticals director Richard A. Heyman exercised stock options to acquire 3,500 shares of common stock at $1.6000 per share and on July 24, 2026 sold a total of 13,100 common shares at $12.0200 per share, including 6,100 shares held through RAHD Capital, LLC. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Heyman and RAHD Capital, LLC. After the option exercise, 30,200 options remained outstanding and RAHD Capital, LLC held 206,672 shares over which he has voting and investment power.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Heyman Richard A.

Role Director

Sold 13,100 shs ($157K)

Approx. gross sale proceeds $157K

Approx. exercise cost $6K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F3	3,500	$0.00	$0.00
Exercise	Common Stock	3,500	$1.60	$6K
Sale	Common Stock F1	7,000	$12.02	$84K
Sale	Common Stock F1, F2	6,100	$12.02	$73K

Holdings After Transaction: Stock Option (right to buy) — 30,200 contracts (Direct); Common Stock — 38,300 shares (Direct); Common Stock — 206,672 shares (Indirect, See footnote)

Footnotes (3)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.
2. F2. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.
3. F3. The shares subject to the option are fully vested and immediately exercisable.

Key Figures

Common shares sold: 13100 shares Sale price per share: $12.0200 Options exercised: 3500 shares +3 more

6 metrics

Common shares sold 13100 shares Total common stock sold on 2026-07-24 (direct and indirect)

Sale price per share $12.0200 Price per share for common stock sales on 2026-07-24

Options exercised 3500 shares Stock options exercised into common stock on 2026-07-24

Option exercise price $1.6000 Exercise price per share for stock options

Options held after exercise 30200.0000 shares Stock options remaining following the reported option exercise

Indirect shares held after sale 206672.0000 shares Common shares held of record by RAHD Capital, LLC after the indirect sale

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy), indirect ownership, voting and investment power

4 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy) financial

"Security titled Stock Option (right to buy) is reported as a derivative"

indirect ownership financial

"Common Stock sale is marked as indirect with nature of ownership "See footnote""

voting and investment power financial

"Reporting Person has voting and investment power with respect to such shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Oric (ORIC) director Richard Heyman report?

Richard A. Heyman reported exercising stock options for 3,500 shares at $1.6000 per share and selling 13,100 common shares at $12.0200 per share on July 24, 2026.

How many Oric (ORIC) shares did Richard Heyman sell and at what price?

He sold 13,100 shares of Oric common stock on July 24, 2026 at a sale price of $12.0200 per share, including 7,000 shares held directly and 6,100 shares held through RAHD Capital, LLC.

What stock options did Richard Heyman exercise in Oric (ORIC)?

Heyman exercised stock options covering 3,500 shares of Oric common stock at an exercise price of $1.6000 per share. After this, options for 30,200 shares remained outstanding, expiring on February 28, 2028.

Were Richard Heyman’s Oric (ORIC) share sales under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Richard A. Heyman and RAHD Capital, LLC, and the Rule 10b5-1 checkbox is marked as affirmative.

What indirect Oric (ORIC) holdings does Richard Heyman report after these trades?

After the reported transactions, 206,672 Oric shares were held of record by RAHD Capital, LLC, over which Richard A. Heyman has voting and investment power, and these are reported as indirect ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/28/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyman Richard A.

(Last) (First) (Middle)

C/O ORIC PHARMACEUTICALS, INC.

240 E. GRAND AVE., 2ND FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oric Pharmaceuticals, Inc. [ ORIC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		M		3,500	A	$1.6	45,300	D
Common Stock	07/24/2026		S(1)		7,000	D	$12.02	38,300	D
Common Stock	07/24/2026		S(1)		6,100	D	$12.02	206,672	I	See footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.6	07/24/2026		M			3,500	(3)	02/28/2028	Common Stock	3,500	$0	30,200	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and RAHD Capital, LLC.

2. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

3. The shares subject to the option are fully vested and immediately exercisable.

	/s/ Christian Kuhlen, attorney-in-fact	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)